Cite
MLA Citation
Kevin Barley et al.. “Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.” American journal of hematology, vol. 95, no. 2, n.d., pp. E51–E54. http://access.bl.uk/ark:/81055/vdc_100099154698.0x000046